Positive results from clinical trials, especially those meeting primary and secondary endpoints, typically lead to increased investor confidence and can drive stock prices up in the short term. Given the significance of these results for a treatment in a potentially large market like MASH, Ionis Pharmaceuticals is likely to see positive movement in its stock price.